Figure 2: Expression of fibronectin in cells, tissues and tumours.
From: MRI detection of breast cancer micrometastases with a fibronectin-targeting contrast agent
(a) The morphology of 4T1 cells with and without TGF-β induction (15 ng ml−1, 5 days). Images were taken by phase-contrast microscopy; all scale bars, 50 μm. (b) RT–PCR analysis demonstrates that treatment with TGF-β induces upregulation of fibronectin and downregulation of E-cadherin, which are characteristic features of EMT, data represent the mean±s.d., n=3. (c) Representative western blots showing fibronectin expression in normal tissues, and in primary and metastatic 4T1 breast tumours in Balb/c mice. (d) Densitometric analysis of the expression of fibronectin normalized to that of β-actin. Values represent mean±s.d., n=3.
